Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?

Ann Oncol. 2019 Jul 1;30(7):1025-1028. doi: 10.1093/annonc/mdz166.

Authors

S L Gaillard¹, R L Coleman²

Affiliations

¹ Departments of Oncology, Johns Hopkins School of Medicine, Baltimore; Gynecology and Obstetrics/Division of Gynecologic Oncology, Johns Hopkins School of Medicine, Baltimore. Electronic address: stephanie.gaillard@jhmi.edu.
² Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, USA.

PMID: 31111866
DOI: 10.1093/annonc/mdz166

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
B7-H1 Antigen*
Female
Humans
Neoplasm Recurrence, Local
Ovarian Neoplasms*

Substances

Antibodies, Monoclonal, Humanized
B7-H1 Antigen
pembrolizumab